Novartis

(IN BRIEF) Novartis announced new MONALEESA pooled analysis results showing that 25% of HR+/HER2- metastatic breast cancer patients treated first-line with Kisqali plus endocrine therapy remained progression-free for four or more years, with a median PFS of 6.8 years. Durable … Read the full press release →

(IN BRIEF) Sandoz has announced the US availability of TYRUKO® (natalizumab-sztn), the first FDA-approved biosimilar to Tysabri® for treating relapsing forms of multiple sclerosis and Crohn’s disease. Developed by Polpharma Biologics, TYRUKO® is clinically equivalent to its reference product and … Read the full press release →

(IN BRIEF) Novartis will present new data from 27 abstracts at the 2025 American College of Rheumatology (ACR) Convergence, featuring late-breaking Phase III results from the NEPTUNUS-1 and NEPTUNUS-2 trials of ianalumab in Sjögren’s disease, which could become the first … Read the full press release →

(IN BRIEF) Novartis announced a definitive agreement to acquire Avidity Biosciences for USD 12 billion in cash, in a move that strengthens its neuroscience franchise and accelerates its xRNA therapeutic strategy. The acquisition brings Avidity’s late-stage programs in myotonic dystrophy … Read the full press release →

(IN BRIEF) Novartis, through its wholly owned subsidiary Torino Merger Sub Inc., has launched a tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at USD 48 per share in cash. The offer commenced September 29, 2025, and … Read the full press release →

(IN BRIEF) Novartis will launch a direct-to-patient (DTP) platform in the US on November 1, 2025, starting with Cosentyx, which will be offered at a 55% discount off list price for cash-paying patients. Cosentyx, a biologic approved for multiple immune-mediated … Read the full press release →

(IN BRIEF) Novartis will present 19 abstracts at the 2025 European Society of Cardiology (ESC) Congress in Madrid, showcasing new findings across its cardiovascular portfolio. Key highlights include two VictORION studies on Leqvio’s impact on quality of life and its … Read the full press release →

(IN BRIEF) Novartis has reported landmark Phase III results showing that ianalumab significantly reduced disease activity in patients with Sjögren’s disease, meeting primary endpoints in both the NEPTUNUS-1 and NEPTUNUS-2 trials. The treatment, which combines B-cell depletion and BAFF-R inhibition, … Read the full press release →

(IN BRIEF) Novartis has appointed Mukul Mehta as CFO and Executive Committee member effective March 16, 2026. He will replace long‑time CFO Harry Kirsch, who retires on March 15, 2026, after 22 years at the company. Kirsch oversaw major strategic … Read the full press release →

(IN BRIEF) From its leadership of key work packages to its rich data resources—the ESC Atlas of Cardiology and GRASP study—the European Society of Cardiology is driving EuroHeartPath’s mission to transform heart-disease care in Europe. This €27 million Horizon Europe … Read the full press release →

(IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoint, showing a significant benefit in radiographic progression-free survival (rPFS) and a positive trend in overall … Read the full press release →

(IN BRIEF) Novartis has presented new data from the Phase III NATALEE trial at ASCO 2025, showcasing Kisqali’s ability to reduce the risk of recurrence in pre-menopausal patients with high-risk early breast cancer. The data reveals a 33% reduction in … Read the full press release →

(IN BRIEF) The Vienna Stock Exchange has expanded its global market offering by allowing the trading of all stocks in the Swiss Market Index (SMI), which includes leading companies like Nestlé, Novartis, Roche, and UBS. This follows the Swiss Federal … Read the full press release →

(IN BRIEF) The European Investment Bank has pledged $60 million to support LeapFrog Investments’ Climate Investment Strategy, a fund aiming to deploy $500 million for green technologies across Africa and Asia. Joined by partners such as IFC, Temasek, and SIFEM, … Read the full press release →

(IN BRIEF) Anette Weber is being put forward for election to the Emmi AG Board of Directors during the General Meeting scheduled for 10 April 2025. With a distinguished career in finance, she has served as CFO at the Bucherer … Read the full press release →

(IN BRIEF) Syngenta has acquired Novartis’ natural products and genetic strains assets to enhance its biologicals research capabilities and support the agricultural sector’s transition to sustainability. This acquisition complements the opening of a state-of-the-art biologicals production facility in South Carolina … Read the full press release →

(IN BRIEF) Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an investigational monoclonal antibody currently in Phase 3 trials for preventing stroke and systemic embolism in patients with atrial fibrillation. This acquisition … Read the full press release →

(IN BRIEF) The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel in London. This event offers a platform for pharma R&D and patient advocacy to discuss … Read the full press release →

(IN BRIEF) The University of St.Gallen and ETH Zurich have partnered to establish the “ETH-HSG Manufacturing Alliance,” aimed at boosting the competitiveness of Swiss industry and nurturing young talent. The alliance is supported by 13 leading industrial partners, including Roche, … Read the full press release →

(IN BRIEF) Holcim has announced its next steps in preparing for the spin-off of its North American business, including the designation of the new Board of Directors. The 10-member Board will become official following shareholder and regulatory approvals, expected by … Read the full press release →